InMed Pharmaceuticals (INM)
Develops cannabinoid-receptor small molecules for neurological, eye, and dermatology diseases.
Something off on this page? Send us feedback.
Develops cannabinoid-receptor small-molecule candidates for Alzheimer's disease, dry AMD, and epidermolysis bullosa-related itch. With its commercial cannabinoid operation winding down, the stand-alone business has no continuing product-sales engine and relies on development, partnering, and financing.
Develops cannabinoid-receptor small molecules for Alzheimer's disease, dry age-related macular degeneration, and epidermolysis bullosa-related itch. The stand-alone pipeline spans a preclinical oral candidate for Alzheimer's, a preclinical intravitreal candidate for dry AMD, and a topical candidate for EB-related itch whose further development is contingent on a partner.
Operates from Vancouver with a small internal team, outsourcing most research and development to scientific collaborators, academic institutions, contract research organizations, and contract development and manufacturing organizations. BayMedica, formerly the sole revenue-generating commercial operation, is being wound down, leaving no current continuing product-sales engine.
Drug programs have no approvals and depend on development, regulatory review, external financing, and commercialization partnerships. A pending Mentari combination would transfer management and future development focus if its closing conditions are met; until then, the stand-alone business remains a cannabinoid-drug developer.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $5.2M · Total debt $420.1K · Total assets $9.1M · Shareholders' equity $6.9M
- Revenue
- $0
- Operating income
- −$2.8M
- Net income
- −$3.0M
No dividends on record.
| Strategic holders3 holders · as of Jul 17, 2026 | 57.31% | 1.90M shares | |
| Otherremainder | 42.69% | 1.41M shares |
3.31M company shares as of Sep 3, 2026 · holders as of their latest filing
Two share counts disagree (3.31M in the company's Sep 3, 2026 report, 1.81M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vivo Opportunity, LLCStrategic10 percent owner | 24.68% | 818,076 | Form 4filed Jul 16, 2026 ↗ |
ADAR1 Capital Management, LLCStrategic10 percent owner | 24.17% | 801,000 | Form 4filed Jul 17, 2026 ↗ |
Squadron Master Fund LPInstitution | 9.81% | 325,000 | 13Gfiled May 27, 2026 ↗ |
Sabby Management, LLCStrategic | 8.45% | 280,138 | 13Gfiled Jan 20, 2026 ↗ |
Empery Asset Management, LPInstitution | —4.99% of class, as filed | — | 13G/Afiled Jan 20, 2021 ↗ |
| See all 16 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 15, 2026 | ADAR1 Capital Management, LLC | 10 percent owner | +1,000 | $1.56 |
| Jul 14, 2026 | Vivo Opportunity, LLC | 10 percent owner | +5,375 | $1.55 |
| Jul 15, 2026 | Vivo Opportunity, LLC | 10 percent owner | +15,150 | $1.55 |
| Jul 16, 2026 | Vivo Opportunity, LLC | 10 percent owner | +21 | $1.55 |
| Jun 30, 2026 | Vivo Opportunity, LLC | 10 percent owner | +600 | $1.54 |
- Biogen
Commercial rivals in early Alzheimer's disease and geographic atrophy.
- Eli Lilly
Kisunla sets a commercial benchmark in early Alzheimer's disease.
- Krystal Biotech
VYJUVEK treats dystrophic EB wounds in the same rare-disease field.
- Annexon
Late-stage GA program overlaps dry-AMD neuroprotection development.
- Belite Bio (ADR)
Phase 3 GA program contests the dry-AMD treatment opportunity.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| InMed Pharmaceuticals | $1.40 | +2.56% | $2.4M | — | — | 0.6 | −29.8% |
| Biogen | $224.80 | +0.94% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Eli Lilly | $1,166.44 | +0.61% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Krystal Biotech | $372.03 | +0.73% | $10.88B | 46.3 | 43.5 | 24.7 | +24.1% |
| Annexon | $4.96 | +0.41% | $807.7M | — | — | — | — |
| Belite Bio (ADR) | $162.00 | +0.34% | $6.44B | — | — | — | — |
| Median | 39.4 | 28.4 | 13.7 | +24.1% |